InnoCare Pharm announced the approval of the Investigational New Drug to conduct the clinical trial of ICP-189, a novel SHP2 allosteric inhibitor, in combination with furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor, in China.
